Home » Stocks » Kaleido Biosciences

Kaleido Biosciences, Inc. (KLDO)

Stock Price: $6.93 USD 0.00 (0.00%)
Updated Jul 9, 2020 8:08 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 211.32M
Revenue (ttm) n/a
Net Income (ttm) -85.66M
Shares Out 35.96M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $6.93
Previous Close $6.93
Change ($) 0.00
Change (%) 0.00%
Day's Open 7.26
Day's Range 6.86 - 7.48
Day's Volume 143
52-Week Range 2.82 - 10.36

More Stats

Market Cap 211.32M
Enterprise Value 175.79M
Earnings Date (est) Aug 13, 2020
Ex-Dividend Date n/a
Shares Outstanding 35.96M
Float 11.88M
EPS (basic) -2.81
EPS (diluted) -2.85
FCF / Share -2.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.68M
Short Ratio 7.58
Short % of Float 10.19%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.88
Revenue n/a
Operating Income -85.10M
Net Income -85.66M
Free Cash Flow -74.43M
Net Cash 35.53M
Net Cash / Share 1.17
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -53.70%
ROE -121.72%
ROIC -524.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.25*
(91.20% upside)
Low
8.00
Current: 6.93
High
19.00
Target: 13.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-86.66-60.68-27.03
Net Income-86.33-61.74-27.56
Shares Outstanding25.705.114.47
Earnings Per Share-3.36-12.09-6.17
Operating Cash Flow-75.80-46.32-22.50
Capital Expenditures-3.59-3.00-1.41
Free Cash Flow-79.38-49.32-23.90
Cash & Equivalents73.5378.2728.68
Total Debt20.3914.8314.81
Net Cash / Debt53.1463.4413.87
Assets82.3185.3330.75
Liabilities33.4228.3421.93
Book Value48.88-96.24-43.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kaleido Biosciences, Inc.
Country United States
Employees 91

Stock Information

Ticker Symbol KLDO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KLDO

Description

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.